FDA issues emergency authorization for new COVID-19 antibody treatment
The Food and Drug Administration (FDA) recently issued an emergency use authorization (EUA) for the combination treatment of bamlanivimab and etesevimab for COVID-19 patients at high risk for severe infection.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.
Quick, Current, Complete - www.findacode.com